Brief: Carbiotix Streamlines Clinical Study Plan

Carbiotix AB (publ)

19/05/2020 08:04

May 19 (Reuters) - Carbiotix AB (publ)  CRBX.TE :
    * CARBIOTIX STREAMLINES CLINICAL STUDY PLAN TO REDUCE RISK
AND
REACH PROFITABILITY SOONER
    * TO POSTPONE PLANNED PRE-CLINICAL AND CLINICAL STUDIES FOR
CANDIDATES IBD (CBX111) AND HYPERAMMONEMIA (CBX121)
    * LAUNCH IS ESTIMATED TO H2 2021 IN US TO THEN INITIATE
CLINICAL
TRIALS DURING H1 2022 REGARDING IBD (CBX111) AND HYPERAMMONEMIA
(CBX121) TO REACH A BRAND NEW MARKET FOR ITS PREBIOTIC PRODUCTS
FOR GASTRIC HEALTH
    * DECIDED NOT TO DO ANIMAL STUDIES IN PRECLINICAL
DEVELOPMENT

Source text for Eikon:  ID:nWkr44200G 
Further company coverage:  CRBX.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))